Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease.
Virani SS, Woodard LD, Chitwood SS, Landrum CR, Urech TH, Wang D, Murawsky J, Ballantyne CM, Petersen LA.
Am Heart J. 2011 Oct;162(4):725-732.e1. Epub 2011 Aug 25.
Related citations
Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia.
Dansky HM, Bloomfield D, Gibbons P, Liu S, Sisk CM, Tribble D, McKenney JM, Littlejohn TW 3rd, Mitchel Y.
Am Heart J. 2011 Oct;162(4):708-16. Epub 2011 Sep 1.
Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial.
Kelly DJ, Gershlick T, Witzenbichler B, Guagliumi G, Fahy M, Dangas G, Mehran R, Stone GW.
Am Heart J. 2011 Oct;162(4):663-70.
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
AIM-HIGH Investigators.
Am Heart J. 2011 Mar;161(3):538-43. Epub 2011 Feb 2.
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
Am Heart J. 2011 Mar;161(3):471-477.e2. Epub 2011 Feb 2.
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
Jones PH, Goldberg AC, Knapp HR, Kelly MT, Setze CM, Stolzenbach JC, Sleep DJ.
Am Heart J. 2010 Oct;160(4):759-66.
Beyond insurance coverage: usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination Survey.
Spatz ES, Ross JS, Desai MM, Canavan ME, Krumholz HM.
Am Heart J. 2010 Jul;160(1):115-21.
Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events.
Teramoto T, Shimada K, Uchiyama S, Sugawara M, Goto Y, Yamada N, Oikawa S, Ando K, Ishizuka N, Yamazaki T, Yokoyama K, Murata M, Ikeda Y.
Am Heart J. 2010 Mar;159(3):361-369.e4.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on